![Sodium Iodide [131I] Market - Global Forecast to 2030- Product Image](http://www.researchandmarkets.com/product_images/12736/12736463_500px_jpg/sodium_iodide_[131i]_market.jpg)
1h Free Analyst Time
The Sodium Iodide [131I] Market grew from USD 736.80 million in 2024 to USD 779.02 million in 2025. It is expected to continue growing at a CAGR of 5.94%, reaching USD 1.04 billion by 2030.Speak directly to the analyst to clarify any post sales queries you may have.
Sodium Iodide [131I] has emerged as a cornerstone of nuclear medicine and specialized industrial applications, distinguished by its radioisotopic properties and versatility. This compound, enriched with iodine-131, delivers targeted beta and gamma radiation, making it indispensable for diagnostic imaging, therapeutic procedures, and radiotracer studies. Over decades, continuous advancements in production methodologies-from reactor-based fission to accelerator-driven processes-have strengthened supply security and optimized purity standards. Today, as healthcare systems evolve and research institutions seek more precise tools, the role of Sodium Iodide [131I] is expanding beyond conventional boundaries.
Fueled by rising demand for non-invasive diagnostic techniques and personalized therapies, the market is witnessing heightened collaboration between radiopharmaceutical manufacturers, medical device companies, and regulatory bodies. This cooperative framework accelerates innovation in capsule, liquid, and solid formulations, thereby broadening clinical and industrial use cases. As stakeholders navigate shifting regulatory landscapes and emerging trade policies, understanding the foundational characteristics of Sodium Iodide [131I]-its mechanism of action, production pathways, and end-market dynamics-becomes critical for informed decision-making.
This executive summary lays out the transformative shifts shaping the Sodium Iodide [131I] industry, examines the cumulative effects of upcoming U.S. tariffs, delves into key segmentation and regional insights, profiles leading companies, and offers actionable recommendations to guide strategic investments and partnerships.
Transformative Shifts Redefining the Sodium Iodide [131I] Ecosystem
In recent years, the Sodium Iodide [131I] landscape has undergone transformative shifts driven by technological breakthroughs and evolving clinical paradigms. Innovations in hadron and linear accelerators have enhanced accelerator-based production, enabling greater yield consistency and reducing reliance on traditional reactor-based cyclotron irradiation and uranium fission reactors. This transition supports decentralized manufacturing models and improves responsiveness to localized demand in academic institutions and nuclear energy plants.Simultaneously, regulatory agencies have accelerated approval pathways for novel radiopharmaceuticals, streamlining diagnostic imaging and therapeutic applications. Enhanced pharmacovigilance frameworks now prioritize real-time data monitoring, ensuring patient safety while encouraging adaptive trial designs. As a result, manufacturers are investing in advanced liquid and capsule forms tailored for outpatient settings, reflecting a shift toward patient-centric care in oncology and cardiology.
Moreover, the integration of digital health platforms is reshaping supply chain management. Blockchain-enabled traceability and predictive analytics optimize inventory levels for healthcare providers and chemical industries alike, reducing downtime and minimizing waste. These cross-industry collaborations are redefining the competitive landscape, fostering resilience against disruptions, and setting new benchmarks for the quality and accessibility of Sodium Iodide [131I] offerings.
Assessing the 2025 U.S. Tariff Landscape and Its Supply Chain Implications
The United States’ imposition of revised tariffs on precursor materials and finished radioisotopes, effective 2025, has generated significant downstream effects on the Sodium Iodide [131I] supply chain. Increased duty rates on imported uranium fission reactors and cyclotron components have raised production costs for reactor-based facilities, shifting emphasis toward domestic accelerator-based production. Manufacturers are reevaluating sourcing strategies to mitigate exposure to volatile raw material expenses and to sustain margin profiles.Healthcare providers and radiopharmaceutical producers are witnessing elevated unit costs, particularly for solid and liquid formulations delivered through international supply channels. In response, several key players have established joint ventures with domestic cyclotron operators and linear accelerator manufacturers, securing prioritized access and stable pricing. These collaborations are also catalyzing investment in localized irradiation infrastructure, bolstering resilience against future trade policy shifts.
Overall, the cumulative impact of the tariffs is spurring a strategic realignment: stakeholders are diversifying production methods-balancing accelerator-based hadron and linear accelerator capabilities with reactor-based cyclotron and fission operations-while reinforcing partnerships across the value chain to maintain supply continuity and competitive positioning.
Unpacking Key Segmentation Insights Across Type, Form, Production, Application, and End Use
An in-depth view of key segmentation dimensions reveals nuanced growth trajectories across market segments. Considering type, Pure Sodium Iodide [131I] retains dominance in therapeutic procedures thanks to its high specific activity, whereas radiopharmaceutical blends are driving innovation in diagnostic imaging and radiotracer applications. When comparing formulation preferences, capsule form continues to gain traction for outpatient procedures, providing precise dosing and improved patient compliance, while liquid variants support in-hospital administration and rapid biodistribution assessment. Solid form remains critical for long-term storage and research assays.Examining production methodologies, accelerator-based production, harnessing both hadron and linear accelerators, offers scalability and reduced radioactive waste, positioning it as the method of choice for medical isotopes. Conversely, reactor-based production through cyclotron irradiation and uranium fission reactors still underpins large-volume supply for industrial shielding applications and bulk radiopharmaceutical manufacturing. This dual approach ensures balanced capacity to meet both clinical and research demands.
Analysis of application sectors underscores diversified end-use opportunities. In industrial contexts, radiation shielding and radiotracer applications leverage high-purity Sodium Iodide [131I] for safety testing and process monitoring. Medical utilization spans diagnostic imaging, radiopharmaceutical production, and therapeutic procedures, reflecting growing adoption of targeted radionuclide therapies. Research applications, including chemical synthesis and nuclear medicine studies, benefit from standardized isotope batches, enabling reproducible experimental outcomes.
Finally, end-use industry segmentation highlights varying demand drivers. Academic and research institutions prioritize flexible production partnerships for experimental studies, while chemical and biotechnology industries focus on stable supply chains for radiolabeling processes. Healthcare and pharmaceutical entities are scaling up to meet rising patient volumes in oncology and cardiology, and nuclear energy plants rely on consistent shipments for reactor maintenance and calibration protocols.
Key Regional Insights Shaping Market Expansion in the Americas, EMEA, and Asia-Pacific
Regional dynamics exhibit distinctive growth patterns shaped by regulatory frameworks, infrastructure maturity, and healthcare investment levels. In the Americas, robust reimbursement policies and advanced nuclear research facilities have catalyzed adoption of accelerator-based production, with a strong focus on outpatient diagnostic services and targeted radiotherapies. Collaborative networks between academic centers and private manufacturers are accelerating clinical trial pipelines and expanding access to novel radiopharmaceuticals.Europe, Middle East & Africa continues to prioritize integrated supply strategies, combining reactor-based cyclotron operations with emerging accelerator capabilities. Stringent EU regulations have led manufacturers to invest in quality management systems and cold-chain logistics, reinforcing product safety. Meanwhile, healthcare modernization programs in the Middle East and Africa are driving demand for diversified application segments, from industrial radiation monitoring to nuclear medicine research.
In Asia-Pacific, government initiatives supporting ‘Make in’ programs and biotech innovation hubs have incentivized local production through linear accelerators and cyclotron partnerships. The region’s rapidly growing healthcare infrastructure, coupled with rising prevalence of cancer and cardiovascular diseases, is boosting demand for diagnostic imaging and therapeutic procedures. Strategic alliances between multinational corporations and regional players are enhancing technology transfer and capacity expansion.
Competitive Landscape and Company Strategies Driving Innovation and Growth
Leading companies are deploying varied strategies to consolidate market leadership and drive innovation. Cardinal Health, Inc. is augmenting its portfolio with integrated logistics solutions, ensuring temperature-controlled distribution for capsule and liquid formulations. China Isotope & Radiation Corporation has scaled reactor-based production capacity while establishing research collaborations focused on novel radiotracer development. Curium Pharma continues to invest in next-generation accelerator infrastructure, targeting rapid isotope turnaround times for clinical partners.Eckert & Ziegler Radiopharma GmbH has fortified quality assurance programs and expanded its global network of linear accelerator facilities, aiming to reduce batch release cycles. GE Healthcare, Inc. leverages its imaging expertise to develop companion diagnostics that integrate seamlessly with Sodium Iodide [131I]-based procedures. Institute of Isotopes Co., Ltd. remains at the forefront of cyclotron innovation, optimizing irradiation parameters to maximize yield and minimize impurities.
International Isotopes Inc. and Isotope JSC are fostering bilateral production agreements to balance supply across hemispheres, while Jubilant DraxImage Inc. focuses on customizable cold kits for radiotracer applications. Mallinckrodt Pharmaceuticals emphasizes cost-efficiency in reactor-based manufacturing, and MEDSNAB LLC is investing in liquid formulation research for high-throughput diagnostic workflows. Nordion Inc. and NorthStar Medical Technologies, LLC continue to expand their global footprint through joint ventures, targeting seamless service delivery for healthcare and industrial clients.
NTP Radioisotopes SOC Ltd and PDRadiopharma Inc. are pioneering process intensification techniques, enhancing a reactor-based and accelerator-based hybrid model. Shandong Xinhua Pharma and Siemens Healthineers AG explore integrated imaging-therapy platforms, while Telix Pharmaceuticals Limited and Yantai Dongcheng Pharmaceutical Group Co. Ltd. collaborate on region-specific product registrations and market entry strategies.
Actionable Recommendations to Strengthen Competitive Advantage and Supply Resilience
Industry leaders should prioritize strategic investments in hybrid production capabilities that balance accelerator-based and reactor-based methodologies to ensure capacity resilience and cost optimization. Forming cross-sector partnerships-linking radiopharmaceutical developers with advanced logistics providers-will streamline cold-chain distribution and reduce lead times for capsule and liquid products. Engaging proactively with regulatory bodies to shape adaptive approval pathways will accelerate access to novel therapeutic and diagnostic applications.Enhancing digital infrastructure through predictive analytics and blockchain-enabled traceability can mitigate supply disruptions and increase transparency across the value chain. Companies should also explore modular production units to serve regional demand hubs, reducing dependency on centralized facilities. Investing in workforce development and technical training will support the operational excellence required for hadron and linear accelerator operations.
Finally, fostering joint research initiatives with academic and healthcare institutions focused on emerging applications-such as targeted alpha therapies and theranostics-will position organizations at the vanguard of next-generation radiopharmaceutical innovation.
Conclusion: Navigating the Future of Sodium Iodide [131I] with Strategic Foresight
The Sodium Iodide [131I] market stands at a pivotal juncture where technological, regulatory, and geopolitical factors converge to redefine supply and application dynamics. As the industry pivots from traditional reactor-based production toward more flexible accelerator-driven models, stakeholders must adapt to evolving tariff landscapes, regulatory expectations, and shifting patient care paradigms. Deep segmentation analysis reveals opportunities across medical, industrial, and research domains, while regional insights highlight the need for tailored strategies in the Americas, EMEA, and Asia-Pacific.Leading companies are demonstrating how integrated approaches-combining robust quality systems, digital supply chain management, and strategic alliances-can unlock new value and mitigate risks. By implementing the actionable recommendations outlined, industry players can navigate policy uncertainties, capitalize on emerging clinical indications, and sustain growth in an increasingly competitive environment.
Market Segmentation & Coverage
This research report categorizes the Sodium Iodide [131I] Market to forecast the revenues and analyze trends in each of the following sub-segmentations:
- Pure Sodium Iodide [131I]
- Radiopharmaceuticals
- Capsule Form
- Liquid Form
- Solid Form
- Accelerator-Based Production
- Hadron Accelerators
- Linear Accelerators
- Reactor-Based Production
- Cyclotron Irradiation
- Uranium Fission Reactors
- Industrial
- Radiation Shielding
- Radiotracer Applications
- Medical
- Diagnostic Imaging
- Radiopharmaceutical Production
- Therapeutic Procedures
- Research
- Chemical Synthesis
- Nuclear Medicine Research
- Academic & Research Institutions
- Chemical & Biotechnology Industries
- Healthcare & Pharmaceuticals
- Nuclear Energy Plants
This research report categorizes the Sodium Iodide [131I] Market to forecast the revenues and analyze trends in each of the following sub-regions:
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
This research report categorizes the Sodium Iodide [131I] Market to delves into recent significant developments and analyze trends in each of the following companies:
- Cardinal Health, Inc.
- China Isotope & Radiation Corporation
- Curium Pharma
- Eckert & Ziegler Radiopharma GmbH
- GE Healthcare, Inc.
- Institute of Isotopes Co., Ltd.
- International Isotopes Inc.
- Isotope JSC
- Jubilant DraxImage Inc.
- Mallinckrodt Pharmaceuticals
- MEDSNAB LLC
- Nordion Inc.
- NorthStar Medical Technologies, LLC
- NTP Radioisotopes SOC Ltd
- PDRadiopharma Inc.
- Shandong Xinhua Pharma
- Siemens Healthineers AG
- Telix Pharmaceuticals Limited
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
6. Market Insights
8. Sodium Iodide [131I] Market, by Type
9. Sodium Iodide [131I] Market, by Form
10. Sodium Iodide [131I] Market, by Production Method
11. Sodium Iodide [131I] Market, by Application
12. Sodium Iodide [131I] Market, by End-Use Industry
13. Americas Sodium Iodide [131I] Market
14. Asia-Pacific Sodium Iodide [131I] Market
15. Europe, Middle East & Africa Sodium Iodide [131I] Market
16. Competitive Landscape
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
List of Tables
Companies Mentioned
- Cardinal Health, Inc.
- China Isotope & Radiation Corporation
- Curium Pharma
- Eckert & Ziegler Radiopharma GmbH
- GE Healthcare, Inc.
- Institute of Isotopes Co., Ltd.
- International Isotopes Inc.
- Isotope JSC
- Jubilant DraxImage Inc.
- Mallinckrodt Pharmaceuticals
- MEDSNAB LLC
- Nordion Inc.
- NorthStar Medical Technologies, LLC
- NTP Radioisotopes SOC Ltd
- PDRadiopharma Inc.
- Shandong Xinhua Pharma
- Siemens Healthineers AG
- Telix Pharmaceuticals Limited
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
Methodology
LOADING...
